(Q38121137)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Emerging drugs for non-alcoholic steatohepatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

8

Atsushi Nakajima

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

2

Masato Yoneda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

6

Satoru Saito

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Wataru Tomeno

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Kento Imajo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yuji Ogawa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yuichiro Eguchi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

13 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

279-290

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

Nonalcoholic fatty liver disease

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Hepatocellular carcinoma with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Non-alcoholic fatty liver disease from pathogenesis to management: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Diagnosis and therapy of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Dyslipidemia in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Effects of 1-O-hexyl-2,3,5-trimethylhydroquinone on carbon tetrachloride-induced hepatic cirrhosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Endpoints and clinical trial design for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Human fatty liver disease: old questions and new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Role of bile acids and bile acid receptors in metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

PPAR delta as a therapeutic target in metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

A novel approach to enhancing cellular glutathione levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Targeting antioxidants to mitochondria by conjugation to lipophilic cations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Therapeutic potential of dithiolethiones for hepatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.811232

10.1517/14728214.2013.811232

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23848366%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference